CAPhO 2024 Sponsored Symposium Merck - New Frontiers in Early-Stage Cancer: Evaluating System Capacity and Leveraging Technology to Support Delivery of Care in the Age of Immunotherapy
Details
The role of pharmacists continues to evolve with the advent of neoadjuvant and adjuvant immunotherapies for the treatment of early-stage cancer. These advances come with an increased need for new technology to support delivery of care to patients and optimize healthcare system capacity.
This program will provide an overview of recent approvals of neoadjuvant and adjuvant immunotherapy and the growing role of pharmacists as key members of the multidisciplinary team. Speakers will discuss the impact of immunotherapy on the healthcare system and evaluate the use of new tools and best practices that are applicable across early and metastatic stages of cancer.
Learning Objectives:
- Review and evaluate the impact of recent adjuvant immunotherapy indications on both patient outcomes and healthcare system capacity
- Explain how oncology pharmacists can contribute to optimizing healthcare system capacity for recent immunotherapy indications
- Introduce new tools to support pharmacists when providing care to patients receiving treatment with immunotherapy
Sponsored by Merck
